Date: 2012-12-11
Type of
information: Interim results
phase: 1-2a
Announcement: updates on four early clinical trials
Company: Innate Pharma (France)
Product: lirilumab or IPH2102/BMS-986015
Action
mechanism:
- monoclonal antibody/immune checkpoint inhibitor. Lirilumab or IPH2102/BMS-986015 is a fully human monoclonal antibody blocking interaction between Killer cell immunoglobulin-like receptors (KIR) on NK cells with their ligands. Blocking these receptors facilitates activation of NK cells and, potentially, destruction of tumor cells by the latter.
Disease: multiple myeloma
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- Innate Pharma has reported updates on four early clinical trials with IPH2101 (hybridoma anti-KIR antibody) in multiple myeloma:
• Interim data of Phase I trial KIRIMID have been presented at ASH: a poster describing interim data from the Phase I study KIRIMID, investigating the safety and tolerability of the combination of IPH2101 with lenalidomide in patients with relapsed multiple myeloma following one or two lines of prior therapy was presented at the 2012 American Society of Hematology (“ASH”) meeting by Don Benson, MD, PhD (Division of Hematology/ Oncology, Ohio State Cancer Center, Columbus, OH).
• Publication of Phase I results of IPH2101 in multiple myeloma in Blood: the results of the trial of IPH2101 in 32 patients with relapsed/refractory multiple myeloma were published online in the journal Blood. Patients were treated with IPH2101 for up to 4 cycles without achieving dose-limiting toxicity (DLT) or reaching maximal tolerated dose (MTD). Analysis of PK data demonstrated a clear relationship between dose and drug concentration.
• Innate Pharma also reports the results of the Phase IIa trials REMYKIR and KIRMONO.
IPH2101, tested as a single agent in patients with stable measurable multiple myeloma after induction therapy (REMYKIR study) and in patients with previously untreated smoldering myeloma (KIRMONO study), did not show significant reductions in M-protein levels, the primary efficacy endpoint of the studies. The safety profile of IPH2101 was satisfactory.
Is
general: Yes
